Ciclesonide
Active ingredient · 2 therapeutic classes
Sold as ALVESCO · OMNARIS
- Drug class
- Glucocorticoids
- Availability
- Prescription only
- Routes
- Nasal, Inhalation
- Markets covered
- 3
- Products on record
- 35
- FDA reports (12 mo)
- 744
Overview
Ciclesonide is an active pharmaceutical ingredient in the Glucocorticoids group (R03BA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 31 | April 10, 2026 |
| CA Canada | Health Canada | 3 | March 22, 2025 |
| US United States | FDA | 1 | November 8, 2022 |
GBUnited Kingdom· MHRA
31 products
Uses
Ciclesonide Advanz Pharma is indicated in treatment to control persistent asthma in adults and adolescents (12 years and older).
How to take
CACanada· Health Canada
3 products
Uses
AND CLINICAL USE ........................................................................... 3 CONTRAINDICATIONS ................................................................................................. 3 WARNINGS AND PRECAUTIONS ...............................................................................
4 ADVERSE REACTIONS ................................................................................................. 8 DRUG INTERACTIONS ...............................................................................................
12 DOSAGE AND ADMINISTRATION ........................................................................... 13 OVERDOSAGE .............................................................................................................. 15 ACTION AND CLINICAL PHARMACOLOGY ..........................................................
15 STORAGE AND STABILITY ....................................................................................... 18 DOSAGE FORMS, COMPOSITION AND PACKAGING........................................... 18 PART II: SCIENTIFIC INFORMATION..............................................................................
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE OMNARIS Nasal Spray is a corticosteroid indicated for treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
1 Treatment of Seasonal Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. 2 Treatment of Perennial Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older.
How to take
Drug interactions
Known interactions involving Ciclesonide. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB567340012 · revised April 10, 2026
- [2]Health Canada (DPD) · 02285606 · revised March 22, 2025
- [3]FDA DailyMed · 15fefd46-ac7e-40… · revised November 8, 2022 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.